Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 6 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Blood biomarker test (p-tau217 / amyloid ratio) Care, carers and services | Treatment |
No effect
whyDirection is for the blood test's ability to detect treatment-related amyloid clearance on PET: AUC 0.61, which the authors call suboptimal and not currently usable for that purpose. It says nothing about the drug's effect. |
Detection of PET-confirmed amyloid clearance after donanemab (AUC at 52 weeks) | phase 3 trial | 830 | Plasma p-tau217 showed suboptimal performance in detecting TRAC by PET in donanemab-treated participants (N = 830), with an area under the ROC curve of 0.61 at 52 weeks |
Alzheimer's & Dementia
2026 ✓ Peer-reviewed PMID 42565262 |
| Physical activity (general / dose) Exercise and activity | Prevention |
No effect
whyNo difference between aerobic training and stretching/balance. Cognition was stable in both arms, but with no non-exercising control the trial cannot say whether either arm helped. |
ADAS-Cog-Exec 12-month cognitive trajectory | phase 3 trial | 296 | Between-group cognitive difference -0.078 (SE 0.074, p=0.3); 12-month hippocampal volume loss 0.51% in both arms |
Alzheimer's & Dementia
2025 ✓ Peer-reviewed PMID 40271888 |
| Anti-tau therapy Medicines | Treatment |
No effect
whyCo-primary endpoints were not met at 52 weeks. The comparator was a low dose of the same drug rather than placebo, which the authors say masked any separation; they report separation in the MCI subgroup only at 78 and 104 weeks. |
ADAS-cog11 and ADCS-ADL23 at 52 weeks (co-primary) | phase 3 trial | 598 | "It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog11 and ADCS-ADL23) at 52 weeks due to symptomatic activity in the control arm." In MCI, ADAS-cog13 differences between early- and delayed-start HMTM 16 mg/day reached p=0.0291 at 78 weeks and p=0.0308 at 104 weeks; NfL progression fell (p=0.0291) and tau pathology (p-tau217) fell (p=0.0165) in MCI |
The Journal of Prevention of Alzheimer's Disease
2026 ✓ Peer-reviewed PMID 41570392 |
| GLP-1 receptor agonist Medicines | Treatment | No effect | CDR-SB | phase 3 trial | 3,808 | EVOKE difference -0.08 (95% CI -0.35 to 0.20); EVOKE+ difference 0.10 (95% CI -0.17 to 0.38) |
The Lancet
2026 ✓ Peer-reviewed PMID 41865758 |
| Other investigational drug Medicines | Treatment | No effect | ADAS-Cog12 and ADCS-ADL (co-primary) at week 52 | phase 3 trial | 804 | ADAS-COG12 change from baseline to week 52: 2.8 (SE 0.36) simufilam vs 3.2 (0.36) placebo, difference -0.39 (0.50), P=0.43. ADCS-ADL: -3.3 (0.44) vs -3.8 (0.44), difference 0.51 (0.61), P=0.40 |
GlobeNewswire (company press release); trial registered as NCT04994483
2024 ⚠ Press release — not a study no DOI or PMID exists |
| Psychotropics for agitation / psychosis Medicines | Treatment |
No effect
whyNot effective, and drug-related QT prolongation was observed. The randomised sample was smaller than planned. |
Clinically significant improvement in agitation at 12 weeks | phase 3 trial | 173 | Risk difference for clinically significant improvement 0.08 (95% CI -0.21 to 0.06) |
Nature Medicine
2025 ✓ Peer-reviewed PMID 40133524 |